298 related articles for article (PubMed ID: 29595004)
1. [Mechanisms and implications of cancer cell dormancy in head and neck carcinoma].
Xiaolei G; Xinhua L; Yaling T
Hua Xi Kou Qiang Yi Xue Za Zhi; 2018 Feb; 36(1):92-98. PubMed ID: 29595004
[TBL] [Abstract][Full Text] [Related]
2. Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis.
Gao XL; Zhang M; Tang YL; Liang XH
Onco Targets Ther; 2017; 10():5219-5228. PubMed ID: 29138574
[TBL] [Abstract][Full Text] [Related]
3. The Relationship Between Dormant Cancer Cells and Their Microenvironment.
Linde N; Fluegen G; Aguirre-Ghiso JA
Adv Cancer Res; 2016; 132():45-71. PubMed ID: 27613129
[TBL] [Abstract][Full Text] [Related]
4. Cellular dormancy in minimal residual disease following targeted therapy.
Ruth JR; Pant DK; Pan TC; Seidel HE; Baksh SC; Keister BA; Singh R; Sterner CJ; Bakewell SJ; Moody SE; Belka GK; Chodosh LA
Breast Cancer Res; 2021 Jun; 23(1):63. PubMed ID: 34088357
[TBL] [Abstract][Full Text] [Related]
5. Cancer Cell Dormancy in Metastasis.
Summers MA; McDonald MM; Croucher PI
Cold Spring Harb Perspect Med; 2020 Apr; 10(4):. PubMed ID: 31548220
[TBL] [Abstract][Full Text] [Related]
6. Tumor dormancy and cancer stem cells: two sides of the same coin?
Kleffel S; Schatton T
Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
[TBL] [Abstract][Full Text] [Related]
7. The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
Allgayer H; Aguirre-Ghiso JA
APMIS; 2008; 116(7-8):602-14. PubMed ID: 18834405
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse.
Muzes G; Sipos F
Anticancer Agents Med Chem; 2017; 17(4):472-482. PubMed ID: 27592547
[TBL] [Abstract][Full Text] [Related]
9. Tumor dormancy: long-term survival in a hostile environment.
Quesnel B
Adv Exp Med Biol; 2013; 734():181-200. PubMed ID: 23143980
[TBL] [Abstract][Full Text] [Related]
10. Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention.
Wang SH; Lin SY
Exp Hematol Oncol; 2013 Oct; 2(1):29. PubMed ID: 24502434
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
Diel IJ; Cote RJ
Cancer Treat Rev; 2000 Feb; 26(1):53-65. PubMed ID: 10660491
[TBL] [Abstract][Full Text] [Related]
12. Clinical opportunities and challenges in targeting tumour dormancy.
Hensel JA; Flaig TW; Theodorescu D
Nat Rev Clin Oncol; 2013 Jan; 10(1):41-51. PubMed ID: 23183631
[TBL] [Abstract][Full Text] [Related]
13. Unveiling cancer dormancy: Intrinsic mechanisms and extrinsic forces.
Liu R; Zhao Y; Su S; Kwabil A; Njoku PC; Yu H; Li X
Cancer Lett; 2024 Jun; 591():216899. PubMed ID: 38649107
[TBL] [Abstract][Full Text] [Related]
14. Dormancy in cancer.
Endo H; Inoue M
Cancer Sci; 2019 Feb; 110(2):474-480. PubMed ID: 30575231
[TBL] [Abstract][Full Text] [Related]
15. Single-Cell Analysis Unveils the Role of the Tumor Immune Microenvironment and Notch Signaling in Dormant Minimal Residual Disease.
Janghorban M; Yang Y; Zhao N; Hamor C; Nguyen TM; Zhang XH; Rosen JM
Cancer Res; 2022 Mar; 82(5):885-899. PubMed ID: 34965936
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Dormancy in Bone.
Clements ME; Johnson RW
Curr Osteoporos Rep; 2019 Oct; 17(5):353-361. PubMed ID: 31468498
[TBL] [Abstract][Full Text] [Related]
17. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells.
Risson E; Nobre AR; Maguer-Satta V; Aguirre-Ghiso JA
Nat Cancer; 2020 Jul; 1(7):672-680. PubMed ID: 33681821
[TBL] [Abstract][Full Text] [Related]
18. Cancer dormancy: a model of early dissemination and late cancer recurrence.
Páez D; Labonte MJ; Bohanes P; Zhang W; Benhanim L; Ning Y; Wakatsuki T; Loupakis F; Lenz HJ
Clin Cancer Res; 2012 Feb; 18(3):645-53. PubMed ID: 22156560
[TBL] [Abstract][Full Text] [Related]
19. PRRX1 Regulates Cellular Phenotype Plasticity and Dormancy of Head and Neck Squamous Cell Carcinoma Through miR-642b-3p.
Jiang J; Zheng M; Zhang M; Yang X; Li L; Wang SS; Wu JS; Yu XH; Wu JB; Pang X; Tang YJ; Tang YL; Liang XH
Neoplasia; 2019 Feb; 21(2):216-229. PubMed ID: 30622052
[TBL] [Abstract][Full Text] [Related]
20. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
